Safety and Immunogenicity Study of the Malaria Vaccines FP9 PP and MVA PP

Inclusion Criteria: * Healthy adults aged 18 to 50 years * Resident in or near Oxford, UK for the duration of the vaccination study * Willingness to allow the investigators to access hospital and General Practitioner medical notes * For females only, willingness to practice continuous effective contraception during the study and if participating, during the subsequent challenge study. * Agreement to refrain from blood donation during the course of the study * Written informed consent * Willingness to undergo an HIV test Exclusion Criteria: * Any deviation from the protocol-defined normal range in biochemistry or haematology blood tests or in urine analysis * Prior receipt of an investigational malaria vaccine * Use of any investigational or non-registered drug, vaccine or medical device other than the study vaccine within 30 days preceding dosing of study vaccine, or planned use during the study period * Administration of chronic immunosuppressive drugs or other immune modifying drugs within six months of vaccination * History of malaria chemoprophylaxis with chloroquine within 5 months prior to the planned challenge, with Lariam within 6 weeks prior to the challenge, and Riamet within 2 weeks prior to the challenge * Any history of malaria * Travel to a malaria endemic country within the previous 6 months prior to the planned challenge * Planned travel to malarious areas during the study period * Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection and asplenia * History of allergic disease or reactions likely to be exacerbated by any component of the vaccine, e.g. egg products * Evidence of cardiovascular disease * History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ) * History of haemoglobinopathies * History of diabetes mellitus * Chronic or active neurological disease * Chronic gastrointestinal disease * History of more than 2 hospitalisations for invasive bacterial infections * Suspected or known current alcohol abuse as defined by an alcohol intake of greater than 42 units every week * Seropositive for hepatitis B surface antigen (HBsAg) * Seropositive for hepatitis C virus (antibodies to HCV) * Hepatomegaly, right upper quadrant abdominal pain or tenderness * Evidence of serious psychiatric condition * Any other on-going chronic illness requiring hospital specialist supervision